Chronic Hepatitis C
PEGASYS, peginterferon alfa-2a, alone or in combination with COPEGUS, is indicated
for the treatment of adults with chronic hepatitis C (CHC) virus infection who
have compensated liver disease and have not been previously treated with interferon
alpha. Efficacy has been demonstrated in subjects with compensated liver disease
and histological evidence of cirrhosis (Child-Pugh class A) and in subjects
with clinically stable HIV disease and CD4 count greater than 100 cells/mm3.
The following points should be considered when initi...
Read the complete drug monograph for Pegasys »